- PROJECTS
- ACTIONS
- Austrian Unit Cost Programme
- BRIDGE Health
- Best-Worst Scaling HTA
- CEQUEL
- Chronic pain
- Exploring the impact of COVID-19 on mental health and wellbeing in Austria – an exploratory study
- Post-COVID-19 Care
- Economic burden of mental health diseases
- ECNP-The physical comorbidity costs of mental health disorders
- ERA PerMedSchiz – PERsonalized MEDicine in SCHIZophrenia
- EVICC
- OxCAP-MH
- ICB questionnaires
- The iLIVE Project, Live well - die well
- Ludwig Boltzmann Institute Applied Diagnostics (LBI AD)
- Mental health 65+ in Austria
- MEQUI-CEE
- nutritionDay Health Economics
- OCTET
- NIHR PAX-BD study: An economic evaluation
- PallPROMs
- PAX-D
- PECUNIA
- PoMeT
- PReDicT
- Public health aspects of migrant health (WHO)
- ACTIONS
- PUBLICATIONS
- PRESENTATIONS
PReDicT
Economic evaluation of the effects of using the eH-ETB (P1vital® eHealth-Emotional Test Battery) to guide the antidepressant treatment of depressed patients
It commonly takes weeks before clinicians are able to identify effective antidepressant (AD) treatment for depressed patients. During this period a patients’ ability to work and function socially is severely impaired by their illness. The P1vital® eHealth-Emotional Test Battery (eH-ETB) is a medical device that is able to identify, early in treatment, whether an AD is working and thus significantly reduce the time required to initiate effective treatment and thereby accelerate remission. The objective of this multi-centre, within-trial cost-utility analysis is to compare societal costs (health and social care resource use, patient costs, informal care, lost productivity) and outcomes (health-related quality of life, social functioning, well-being) of eH-ETB with standard of care in six European countries (Germany, France, Spain, UK, The Netherlands).
Dates:
2015-2019
Funding:
European Commission – Horizon 2020
Collaborator(s):
P1Vital, UK
Information:
Judit Simon, Susanne Mayer, Natasa Peric
Publication(s):
- Browning M, Bilderbeck A, Dias R, Dourish CT, Kingslake J, Deckert J, et al. The Clinical Effectiveness of Using a Predictive Algorithm to Guide Antidepressant Treatment in Primary Care (PReDicT): an open-label, randomised controlled trial. Neuropsychopharmacol. 2021 Feb 26. DOI: 10.1038/s41386-021-00981-z
- Simon J, Perić N, Mayer S, Deckert J, Gorwood P, Pérez V, et al. on behalf of the PReDicT group. Cost-effectiveness of the predict test: results and lessons learned from a european multinational depression trial. EPP0934. Eur Psychiatry. 2020 Jul;63(S1):S45-S282. DOI: 10.1192/j.eurpsy.2020.5
- Simon J, Harmer CJ, Kingslake J, Dawson GR, Colin T D, Goodwin GM: The value of monitoring negative emotional bias in primary care in England for personalised antidepressant treatment: A modelling study. BMJ Evidence Based Mental Health. 2019. DOI:10.1136/ebmental-2019-300109
- Simon J, Perić N, Mayer S, Deckert J, Gorwood P, Pérez V, Reif A., Ruhe H, Veltman D, Morriss R, Bilderbeck A, Dawson G, Dourish C, Dias R, Kingslake J, Browning M, on behalf of the PReDicT group (2019). PMH21 Cost-effectiveness of the Predict Test: Results and Lessons learned from a European Multinational Depression Trial. Value in Health, 22, S. 684. DOI: 10.1016/j.jval.2019.09.1495
- Dawson, GR, Guo, B, Kingslake, J, Ruhe, HG, Veltman, D, Deckert, J, Reif, A., Gorwood, P, Perez, V, Simon, J, Harmer, CJ, Goodwin, GM, Dias, R, Dourish, CT, Bilderbeck, AC, Pearce, L, Campbell, S, Morriss, R, Browning, M (2019): Results of the predict randomised controlled trial: clinical effects of using the predict test to guide antidepressant treatment in depression. European Neuropsychopharmacology, Vol 29, Suppl 6, pp S53-S54, DOI: 10.1016/j.euroneuro.2019.09.112
- Kingslake J, Dias R, Dawson GR, Simon J, Goodwin GM, Harmer CJ, et al. (2017) The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: Study Protocol for a Randomised Controlled Trial. Trials. DOI: 10.1186/s13063-017-2247-2
- Simon J, Kiss N, Łaszewska A, Mayer S (2015): P1VITAL® OXFORD EMOTIONAL TEST BATTERY (PC-ETB): Health economics/market access research assessment (internal report).
Featured
